Thus mutations in DYRK1B that are found in cancer (L28P, R102H, S234G and Q275R) or metabolic syndrome (L28P, R102C) have either no effect on intrinsic kinase activity or reduce kinase activity, in one case (DYRK1BQ275R) severely. This evidence concerns the gene DYRK1B and cancer.